Navigation Links
Watson Confirms Welchol® Oral Suspension Patent Challenge
Date:1/25/2011

MORRISTOWN, N.J., Jan. 25, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Colesevelam HCI powder for oral suspension, 1.875 gm/packet and 3.75 gm/packet.  Watson's Colesevelam HCI powder for oral suspension is a generic version of Daiichi Sankyo, Inc.'s Welchol ® oral suspension, which is indicated to reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia as monotherapy or in combination with an hydroxymethyl-glutarylcoenzyme A (HMG CoA) reductase inhibitor (statin); to reduce LDL-C levels in boys and postmenarchal girls, 10 to 17 years of age with heterozygous familial hypercholesterolemia as monotherapy or in combination with a statin after failing an adequate trial of diet therapy; and to improve glycemic control in adults with type 2 diabetes mellitus.

(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO)

Daiichi Sankyo and Genzyme Corporation filed suit against Watson on January 21, 2011 in the United States District Court for the District of Delaware seeking to prevent Watson from commercializing its product prior to the expiration of U.S. Patent No. 5,693,675.  Daiichi Sankyo's lawsuit was filed under the provisions of the Hatch-Waxman Act, resulting in a stay of final FDA approval of Watson's ANDA until June 19, 2013, or until final resolution of the matter before the court, whichever occurs sooner, subject to any other exclusivities.  

About Watson Pharmaceuticals, Inc.Watson Pharmaceuticals, Inc. is a leading global specialty pharmaceutical company.  The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialize
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Watson Launches Generic Biaxin(R) XL
2. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
3. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
4. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
5. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
6. Watson and Barr Settle Lawsuit Over Oxytrol(R)
7. Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2009 Earnings and 2010 Outlook
8. Watson Completes Acquisition of Eden Biodesign
9. Watson to Present at Credit Suisse Healthcare Conference
10. Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy
11. Watson Files FDA Application for Generic Rozerem(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... , Feb. 26, 2015  Mail-service and specialty ... consumers, employers and government health plans $23.3 billion ... by the Pharmaceutical Care Management Association (PCMA). ... offers one of the easiest ways to reduce ... Mark Merritt . "Policymakers should resist efforts to ...
(Date:2/26/2015)... Research and Markets ( http://www.researchandmarkets.com/research/2vn6hh/radiation_therapy ) ... Equipment - Global Strategic Business Report" report to ... worldwide markets for Radiation Therapy Equipment in US$ Million ... Systems, and Radiation Therapy Simulator. The report provides separate ... , Japan , Europe ...
(Date:2/26/2015)... 26, 2015 The report, ... washer, Filler, Capper, Blow molder, Shrink wrapper), Technology ... Flavored, Sparkling) & Region - Trends & Forecasts ... the bottled water processing market with analyses and ... of value. It also identifies the driving and ...
Breaking Medicine Technology:PCMA: Report Shows High-Tech Specialty and Mail-Service Pharmacies Will Reduce Costs for Texas Employers, Consumers and Public Programs by $23.3 Billion 2Radiation Therapy Equipment - Global Strategic Business Report 2015-2020: Linear Accelerator, Treatment Planning Systems, and Radiation Therapy Simulator 2Bottled Water Processing Market Worth $2,106.5 Million by 2019 2Bottled Water Processing Market Worth $2,106.5 Million by 2019 3Bottled Water Processing Market Worth $2,106.5 Million by 2019 4
... Immucor, Inc. (Nasdaq: BLUD ), a global leader in providing automated ... generation automated instrument, NEO™, has been cleared for marketing in the U.S. ... blood bank instrument designed to meet the needs of high volume laboratories. ... "We believe there is ...
... April 30 A new study, presented at the American Society ... Breast-Specific Gamma Imaging (BSGI) is highly accurate in monitoring the response of ... , , ... in several other studies to improve breast cancer detection and aid in ...
Cached Medicine Technology:Immucor Announces FDA Clearance of NEO, the Company's Fourth Generation Automated Instrument 2BSGI Offers Clear View of Breast Tumor Response to Neoadjuvant Chemotherapy 2
(Date:2/26/2015)... Sierra Madre, CA (PRWEB) February 26, 2015 ... leader in wound center management, recently expanded its executive ... of wound care industry experience. At the same time ... in the company. Wound Care Advantage (WCA) was founded ... wound management companies still operating today. The WCA team ...
(Date:2/26/2015)... 26, 2015 SpendWell Health, an ... launch to its first customer today, opening its ... covered dependents. , SpendWell delivers the next ... combining real-time price transparency with e-commerce. SpendWell’s unique ... routine health care services and allows shoppers to ...
(Date:2/26/2015)... 2015 Catalent Pharma Solutions, ... technologies and development solutions for drugs, biologics ... several expanded capabilities within its European Clinical ... implemented in response to increased customer demand ... of highly-potent or temperature-sensitive investigational medical products ...
(Date:2/26/2015)... February 26, 2015 Participants in ... What’s Working? What’s Not? What’s New? ,” will ... programs to achieve strong outcomes for duals-plan members ... happening in the implementation phase of programs for ... made? Which ones need to be implemented in ...
(Date:2/26/2015)... (PRWEB) February 26, 2015 The Reproductive ... of their newly renovated office in Lawrenceville, NJ. ... Science Center of New Jersey’s physicians, and NJ Top ... patient care in the areas of infertility and reproductive ... having excellent success rates and providing current, high quality ...
Breaking Medicine News(10 mins):Health News:Wound Center Management Leader WCA Expands Its Team to Include Additional Industry Experts 2Health News:Wound Center Management Leader WCA Expands Its Team to Include Additional Industry Experts 3Health News:Wound Center Management Leader WCA Expands Its Team to Include Additional Industry Experts 4Health News:SpendWell Launches New Online Health Care Marketplace to Large Employer Group 2Health News:SpendWell Launches New Online Health Care Marketplace to Large Employer Group 3Health News:Catalent Expands European Clinical Packaging Capabilities, Highlighting Growing Industry Need for Specialty Handling 2Health News:Catalent Expands European Clinical Packaging Capabilities, Highlighting Growing Industry Need for Specialty Handling 3Health News:Upcoming AIS Virtual Conference Will Explain What Is and Is Not Working in Medicare-Medicaid Dual Eligibles Programs 2Health News:RSCNJ Is Celebrating the Reopening of Their Newly Renovated Office 2Health News:RSCNJ Is Celebrating the Reopening of Their Newly Renovated Office 3
... , LITTLE FALLS, N.J. , Jan. 20 Which ... Past Week. , Most Read Stories for the Past Week will be published Every Monday and will be available by visiting ... OTC D r ... SCCM: Toddler Fou n d Fro z e ...
... ... January 2 of this year, Freedom From Covert Harassment and Surveillance (FFCHS) ... event coincides with January as National Stalking Awareness Month. Organized stalking, ... not even know why the stalking is occurring, has emerged with the ...
... ... interested clients for home healthcare services. Please contact us if you are interested and ... or potential clients and their families as required by federal HIPAA laws. , ... (PRWEB) January 20, 2010 -- Nurse Hodgkins ...
... ... from All Home Security, an online resource for home security and safety. , ... New York (PRWEB) January 20, 2010 ... own vulnerability to natural disaster. FEMA classifies residents in 40 states as being ...
... 2010) Researchers at the University of Minnesota and ... in the brains of those exhibiting post-traumatic stress disorder ... were involved in the study, which for the first ... measurement of magnetic fields in the brain. It,s something ...
... ... and relief workers to help in the aftermath of the Haitian earthquake , ... New York (PRWEB) January ... doctors, nurses, emergency medical technicians and Scientology Volunteer Ministers to Port-au-Prince where ...
Cached Medicine News:Health News:MedPage Today(R) 'What Your Physicians Are Reading' 2Health News:MedPage Today(R) 'What Your Physicians Are Reading' 3Health News:FFCHS Launches Online Petition Against Organized Stalking and Electronic Torture 2Health News:FFCHS Launches Online Petition Against Organized Stalking and Electronic Torture 3Health News:FFCHS Launches Online Petition Against Organized Stalking and Electronic Torture 4Health News:Earthquake Safety a Concern for Americans 2Health News:Researchers discover method to objectively identify PTSD 2Health News:Scientology-Sponsored Charter Flight Brings Medical and Spiritual Aid to Haiti 2
... The PowerEase® 500 Power ... mini-gel electrophoresis. It offers extensive ... and four custom methods for ... own preferences. The simple, intuitive ...
Power Supply E865 is ideal for electrophoresis and semi-dry blotting applications. The electrical leads from Hoefer Gel apparatus are fully compatible with this new E865 power supply and there is no ...
EPS 3501 : 3500 V, 150 mA, 100 W maximum. Constant voltage, constant current, or constant power modes. Stores and recalls three protocols. Excellent for manual DNA sequencing and IEF applications....
... supply, with temperature probe, 100-120 and 220-240 V, ... mA, and 400 W. The temperature probe is ... 90 degrees C during electrophoresis. Built-in infrared capability ... instructions are provided. Dimensions are 27.5 x 34 ...
Medicine Products: